Platelets—blood cells continuously produced from megakaryocytes mainly in the bone
marrow—are implicated not only in haemostasis and arterial thrombosis, but also in other …

Implantation of drug-eluting stents (DES) is the dominant treatment strategy for patients with
symptomatic coronary artery disease. However, the first-generation DES had substantial …

Background There is a paucity of data on the burden of in-stent restenosis (ISR) in the
United States as well as on its presentation and appropriate treatment strategies. Objectives …

Background Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR)
may still occur in as many as 2–10% of percutaneous coronary interventions (PCI) in certain …

Stent thrombosis (ST) is a rare but severe complication of coronary procedures with high
mortality, high relapse rate and a very complex pathophysiology. An individual's …

Ischemic heart disease is one of the leading causes of morbidity and death worldwide.
Consequently, myocardial infarctions are often encountered in clinical and forensic …

Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has
dramatically improved by overcoming several challenges. The introduction of drug-eluting …

Cardiovascular diseases have become one of the leading causes of mortality worldwide.
Stents and artificial grafts have been used to treat cardiovascular diseases. Thrombosis and …

Stents are lifesaving mechanical devices that re-establish essential blood flow to the
coronary circulation after significant vessel occlusion due to coronary vessel disease or …

Drug-eluting stents (DESs) placement remarkably reduces the over-proliferation of smooth
muscle cells (SMCs) and thus neointimal hyperplasia. However, the pharmacological agent …